News | March 18, 2026
Sun Pharma scores FDA review for ILUMYA in psoriatic arthritis
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
The endorsement follows overwhelming support for the share swap preceding the merger,
Cognita CXR leverages a proprietary vision-language model to analyze full chest X-ray studies and generate comprehensive preliminary findings
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
If approved, DTX401 would be the first treatment to address the disease at its root cause
BLA is based on a robust data package supporting similarity to Orencia (abatacept) IV for infusion through totality of evidence including pharmacokinetic (PK) data
200+ HR leaders and CXOs convened to discuss workforce health, preventive care, and organisational wellbeing as strategic business priorities
Subscribe To Our Newsletter & Stay Updated
